| scholarly article | Q13442814 |
| P50 | author | Arja Jukkola-Vuorinen | Q37069253 |
| Robert Winqvist | Q37074224 | ||
| Anne-Lise Børresen-Dale | Q11958220 | ||
| Ivan Bièche | Q37240788 | ||
| Rosette Lidereau | Q37240861 | ||
| Jórunn Erla Eyfjörd | Q41606335 | ||
| Pierre Hainaut | Q50585710 | ||
| Charles Theillet | Q55664894 | ||
| Patrizia Carrieri | Q56335239 | ||
| Magali Olivier | Q57419614 | ||
| Anita Langerød | Q65594287 | ||
| Jonas Bergh | Q104287348 | ||
| P2093 | author name string | Dieter Niederacher | |
| Carmen Rodriguez | |||
| Chikashi Ishioka | |||
| Shunsuke Kato | |||
| Nancy Uhrhammer | |||
| Sigrid Klaar | |||
| Jennifer Varley | |||
| Yves Bignon | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| patient | Q181600 | ||
| P304 | page(s) | 1157-67 | |
| P577 | publication date | 2006-02-15 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer | |
| P478 | volume | 12 |
| Q37589207 | 30 years and a long way into p53 research |
| Q35176681 | A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk |
| Q24312083 | A Pin1/mutant p53 axis promotes aggressiveness in breast cancer |
| Q36120749 | A comparison of multiscale methods for the analysis of molecular dynamics simulations |
| Q36990777 | A microscopic landscape of the invasive breast cancer genome |
| Q60035707 | A prognostic DNA signature for T1T2 node-negative breast cancer patients |
| Q92597792 | A protein-centric approach for exome variant aggregation enables sensitive association analysis with clinical outcomes |
| Q37143757 | A radiation-derived gene expression signature predicts clinical outcome for breast cancer patients |
| Q34577709 | A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer |
| Q35218636 | A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage |
| Q40143097 | AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway |
| Q53437314 | Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes. |
| Q37132255 | Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer |
| Q33908211 | Adiposity is associated with p53 gene mutations in breast cancer |
| Q43153275 | Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer |
| Q33865095 | Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation |
| Q46219855 | Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. |
| Q38730179 | Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells |
| Q35906322 | Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
| Q34004105 | Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803 |
| Q58002983 | Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer |
| Q46468190 | Association of p53 Codon 72 Polymorphism with Breast Cancer in a Rwandese Population |
| Q37387457 | Association of prediagnostic physical activity with survival following breast cancer diagnosis: influence of TP53 mutation status |
| Q54582432 | Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. |
| Q30497664 | BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations |
| Q33598054 | Bioinformatics analysis of the prognostic value of Tripartite Motif 28 in breast cancer |
| Q37315121 | Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration |
| Q57107513 | Breast cancer in adolescents and young adults |
| Q27612411 | CIViC database |
| Q26743510 | Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes |
| Q33733991 | Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance |
| Q33299319 | Changes in allelic imbalances in locally advanced breast cancers after chemotherapy |
| Q36777343 | Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson |
| Q92551228 | Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts |
| Q33903965 | Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance |
| Q38906201 | Clinical Outcomes of TP53 Mutations in Cancers |
| Q33693838 | Clinical outcomes and correlates of TP53 mutations and cancer |
| Q91526471 | Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers |
| Q87202670 | Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database |
| Q39135886 | Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients |
| Q90460653 | Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) |
| Q53086894 | Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer. |
| Q33627208 | Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients |
| Q40203060 | Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer |
| Q57556283 | Comparison of DGGE and immunohistochemistry in the detection of TP53 variants in a Brazilian sample of sporadic breast tumors |
| Q38743201 | Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines |
| Q34821135 | Consensus recommendations for advancing breast cancer: risk identification and screening in ethnically diverse younger women |
| Q36746295 | Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activity |
| Q35175479 | Deep mutational scanning: assessing protein function on a massive scale |
| Q37688860 | Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes |
| Q33802545 | Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers |
| Q38881649 | Diagnosis and Management of Hereditary Adrenal Cancer |
| Q91964954 | Do Mutations Turn p53 into an Oncogene? |
| Q34103978 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary |
| Q47674627 | Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. |
| Q36127825 | Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer |
| Q34457187 | Epigenetic linkage of aging, cancer and nutrition |
| Q33794029 | Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A |
| Q38747225 | Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer. |
| Q38134099 | Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor |
| Q36225122 | Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women |
| Q21245738 | Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters |
| Q21092375 | Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen |
| Q91675540 | FAM53A Affects Breast Cancer Cell Proliferation, Migration, and Invasion in a p53-Dependent Manner |
| Q41130119 | Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution |
| Q39506267 | Functional significance of Aurora kinase A regulatory interactions with p53-ERα complex in human breast cancer cells |
| Q48863873 | Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. |
| Q36728818 | Gene-expression analysis and the basal-like breast cancer subtype |
| Q37453787 | Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis |
| Q26770339 | Genetic causes of cancer predisposition in children and adolescents |
| Q35190796 | Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer |
| Q49884832 | Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. |
| Q37057145 | Genomic and Epigenomic Alterations in Cancer |
| Q35726998 | Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes |
| Q38539917 | Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. |
| Q34480707 | Hereditary ovarian cancer: not only BRCA 1 and 2 genes. |
| Q55058635 | High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. |
| Q35682017 | High frequency of complex TP53 mutations in CNS metastases from breast cancer. |
| Q54541666 | High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. |
| Q34613059 | Household income is associated with the p53 mutation frequency in human breast tumors |
| Q38931858 | Human pancreatic cancer progression: an anarchy among CCN-siblings |
| Q39285924 | IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes |
| Q52647660 | Identification of p53 and its isoforms in human breast carcinoma cells. |
| Q29616468 | Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database |
| Q28238397 | Initial steps of metastasis: cell invasion and endothelial transmigration |
| Q90388825 | Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer |
| Q36906240 | Interaction between p53 and estradiol pathways in transcriptional responses to chemotherapeutics |
| Q96304262 | Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells |
| Q36319385 | Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells |
| Q34294432 | Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature |
| Q26864033 | Links between mutant p53 and genomic instability |
| Q38130105 | Lobular breast cancer: pathology, biology, and options for clinical intervention |
| Q39564361 | Loop domain organization of the p53 locus in normal and breast cancer cells correlates with the transcriptional status of the TP53 and the neighboring genes |
| Q58550839 | Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV |
| Q35737352 | Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. |
| Q35694610 | MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. |
| Q34093947 | Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. |
| Q41169679 | MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells |
| Q33399356 | Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences |
| Q28546597 | Modulation of the disordered conformational ensembles of the p53 transactivation domain by cancer-associated mutations |
| Q51759206 | Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. |
| Q39399933 | Molecular and clinicopathological markers of prognosis in breast cancer. |
| Q61447145 | Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study |
| Q57280932 | Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) |
| Q34374191 | Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes |
| Q35522196 | Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival |
| Q39009607 | Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. |
| Q24302433 | Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway |
| Q34288205 | Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. |
| Q39229004 | Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy |
| Q38959098 | Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice |
| Q35729171 | Mutant p53 protein expression and antioxidant status deficiency in breast cancer |
| Q36070574 | Mutant p53: one name, many proteins |
| Q36685492 | Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. |
| Q33703486 | Mutations in p53, p53 protein overexpression and breast cancer survival |
| Q37903701 | Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis |
| Q48205560 | Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies |
| Q58068775 | Novel Insights into Combating Cancer Chemotherapy Resistance Using a Plasmonic Nanocarrier: Enhancing Drug Sensitiveness and Accumulation Simultaneously with Localized Mild Photothermal Stimulus of Femtosecond Pulsed Laser |
| Q41808246 | Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. |
| Q34566248 | Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma |
| Q34882515 | Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status |
| Q35022751 | P16 and p53 play distinct roles in different subtypes of breast cancer |
| Q37982133 | P53 and its molecular basis to chemoresistance in breast cancer |
| Q38238609 | PI3K/Akt-mediated regulation of p53 in cancer |
| Q46458121 | PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. |
| Q45831582 | Parallel progression of primary tumours and metastases |
| Q99408595 | Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q38778616 | Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients. |
| Q30389604 | Pharmacological reactivation of mutant p53: from protein structure to the cancer patient |
| Q47772405 | Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer |
| Q37043109 | Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. |
| Q59812268 | Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis |
| Q36385696 | Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway |
| Q61809891 | Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma |
| Q33898517 | Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population |
| Q58744379 | Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients |
| Q83397081 | Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients |
| Q33363261 | Prions, amyloids, and RNA: Pieces of a puzzle. |
| Q33646271 | Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers |
| Q36245341 | Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial |
| Q33739357 | Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX |
| Q55008104 | Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer. |
| Q57298068 | Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer |
| Q90243732 | Protein interaction disruption in cancer |
| Q35722008 | Random mutations, selected mutations: A PIN opens the door to new genetic landscapes |
| Q53686273 | Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. |
| Q36474056 | Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas |
| Q37273304 | Recent advances in p53 research: an interdisciplinary perspective. |
| Q37208757 | Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. |
| Q90186243 | Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil |
| Q30235460 | Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice |
| Q37564385 | Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma. |
| Q60637267 | Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes |
| Q39169881 | Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype. |
| Q37942529 | Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors |
| Q35572905 | Role of traditional and new biomarkers in breast carcinogenesis. |
| Q51097608 | Runx3 and Cell Fate Decisions in Pancreas Cancer. |
| Q37792988 | Selected technologies for measuring acquired genetic damage in humans |
| Q30358684 | Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. |
| Q38922539 | Somatic TP53 Mutations in the Era of Genome Sequencing. |
| Q26776018 | Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis |
| Q35749438 | Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas |
| Q35036895 | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients |
| Q35127734 | Structural basis for understanding oncogenic p53 mutations and designing rescue drugs |
| Q36786022 | Structural biology of the tumor suppressor p53 and cancer-associated mutants |
| Q36941044 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. |
| Q36777367 | Structure-function-rescue: the diverse nature of common p53 cancer mutants |
| Q93101350 | Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment |
| Q58792318 | Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity |
| Q30377229 | Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers |
| Q37203299 | Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo |
| Q36889861 | TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients |
| Q36376097 | TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays |
| Q89727347 | TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines |
| Q38999130 | TP53 Mutations in Breast and Ovarian Cancer |
| Q36135744 | TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution |
| Q41733541 | TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family |
| Q38180665 | TP53 mutants in the tower of babel of cancer progression |
| Q42263612 | TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients. |
| Q36148592 | TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes |
| Q39030842 | TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. |
| Q55278806 | TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer. |
| Q37362747 | TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting |
| Q41519051 | TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer |
| Q90443964 | TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database |
| Q89956023 | TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies |
| Q36777326 | TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes |
| Q33685392 | TP53 mutations in human cancers: origins, consequences, and clinical use |
| Q35043933 | TP53 status and response to treatment in breast cancers |
| Q34576275 | TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy |
| Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
| Q24336227 | The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells |
| Q28484331 | The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk |
| Q24298743 | The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer |
| Q39018419 | The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence |
| Q83509266 | The TP53 gene polymorphisms and survival of sporadic breast cancer patients |
| Q35683528 | The amplifier effect: how Pin1 empowers mutant p53 |
| Q53548810 | The clinical value of LRRC3B gene expression and promoter hypermethylation in breast carcinomas. |
| Q28473733 | The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound |
| Q37602507 | The expanding universe of p53 targets |
| Q27863460 | The genetics of the p53 pathway, apoptosis and cancer therapy |
| Q27027865 | The p53-estrogen receptor loop in cancer |
| Q47106643 | The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma. |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q34391735 | The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. |
| Q35083487 | The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder |
| Q46590951 | The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q34814407 | Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells |
| Q64106473 | Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene |
| Q33685568 | Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression. |
| Q34324683 | Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions |
| Q49435928 | Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q37623308 | YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins |
| Q39096715 | p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. |
| Q35029530 | p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. |
| Q33723628 | p53 mutation, deprivation and poor prognosis in primary breast cancer |
| Q53226865 | p53 mutations and inflammation-associated cancer are linked through TNF signaling. |
| Q39692880 | p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines |
| Q37248542 | p53: a molecular marker for the detection of cancer. |
Search more.